Association between the insulin-like growth factor 1 gene rs2195239 and rs2162679 polymorphisms and cancer risk: a meta-analysis

Table 3 Meta-analysis of the association between rs2195239 and rs2162679 polymorphisms and cancer risk

Subgroup	No.	Allele model			Homozygote model			Heterozygote model			Dominant model			Recessive model
		OR(95% Cl)	P _OR	P _h	OR(95% Cl)	P _OR	P _h	OR(95% Cl)	P _OR	P _h	OR(95% Cl)	P _OR	P _h	OR(95% Cl)	P _OR	P _h
rs2195239		C vs. G			CC vs. GG			GC vs. GG			CC + GC vs. GG			CC vs. GC + GG
Overall	8	0.97(0.93–1.01)	0.103	0.722	0.88(0.80–0.98)	0.018	0.454	1.00 (0.93–1.10)	0.972	0.526	0.97(0.90–1.05)	0.466	0.659	0.95 (0.90–1.01)	0.083	0.162
Asian	3	0.91 (0.82–1.00)	0.044	0.906	0.81 (0.66–0.99)	0.035	0.731	0.96 (0.83–1.12)	0.616	0.534	0.92 (0.79–1.06)	0.232	0.831	0.83 (0.69–0.98)	0.031	0.362
Breast cancer	3	0.97(0.93–1.02)	0.282	0.939	0.91 (0.81–1.03)	0.152	0.294	0.99 (0.89–1.10)	0.866	0.238	0.97(0.87–1.07)	0.536	0.474	0.97(0.91–1.03)	0.308	0.131
Pancreatic cancer	2	1.02 (0.89–1.16)	0.833	0.139	0.94 (0.67–1.31)	0.710	0.134	1.11 (0.92–1.34)	0.275	0.921	1.08 (0.91–1.30)	0.466	0.600	0.88(0.51–1.51)^*	0.640	0.087
rs2162679		G vs. A			GG vs. AA			AG vs. AA			GG + AG vs. AA			GG vs. AG + AA
Overall	5	0.87 (0.80–0.94)	0.001	0.693	0.70 (0.57–0.87)	0.001	0.787	0.91 (0.82–1.02)	0.209	0.556	0.88(0.79–0.97)	0.011	0.578	0.73 (0.60–0.89)	0.002	0.817
Asian	2	0.85 (0.76–0.96)	0.007	0.302	0.70 (0.54–0.90)	0.005	0.737	0.97(0.71–1.33)^*	0.845	0.096	0.86 (0.74–1.01)	0.065	0.131	0.73 (0.57–0.92)	0.009	0.824
Quality score ≥ 12	2	0.87 (0.77–0.99)	0.037	0.389	0.67 (0.44–1.00)	0.049	0.385	0.91 (0.78–1.06)	0.225	0.629	0.88(0.76–1.02)	0.093	0.492	0.68 (0.46–1.02)	0.064	0.412

Abbreviations: OR odds ratio, 95% CI 95% confidence interval, P_OR pool P value, P_h P value of heterogeneity test, *indicates that the OR, 95% Cl, and corresponding P_OR were calculated based on the random-effects model; otherwise, the fixed-effects model was used. Bold values are statistically significant (P_OR < 0.05)

ISSN: 1471-2350